GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.

Journal:
Hepatology
Published:
DOI:
10.1097/hep.0000000000001771
Affiliations:
7
Authors:
6
Go to article
Institutions Authors Share
Stanford University, United States of America (USA)
2.833333
 0.47
The University of Hong Kong (HKU), China
0.833333
 0.14
State Key Laboratory of Liver Research, HKU, China
0.833333
 0.14
Stanford Medicine, United States of America (USA)
0.666667
 0.11
VA Palo Alto Healthcare System (VAPAHCS), United States of America (USA)
0.500000
 0.08
The University of Hong Kong - Shenzhen Hospital (HKU-SZH), China
0.333333
 0.06
Interested in Pharmacology and Pharmaceutical Sciences?